67 / 74 · 0:54 · Original AXON film
Thymosin alpha-1
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Thymosin alpha-1 | Patient outcomes matter
Thymosin alpha-1 is studied for effects on immune function. Whether an immune signal changes is a different question from whether patients survive serious illness. [1]
PHASE 3 HUMAN TRIAL | Sepsis
The TESTS trial enrolled more than eleven hundred adults with sepsis across Chinese centres. Participants received thymosin alpha-1 or placebo alongside standard care. [1]
No demonstrated 28-day mortality reduction
The analysis did not demonstrate a reduction in deaths within twenty-eight days. A published correction updated some calculations without turning this into a positive mortality finding. [1] [2]
Keep conclusions tied to the setting
That result applies to this trial and setting. It neither proves all possible uses ineffective nor establishes a general immune-boosting benefit in healthy people. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Wu et al. (2025): The efficacy and safety of thymosin alpha1 for sepsis (TESTS) →1106 enrolled; 1089 in modified intention-to-treat analysis; no demonstrated 28-day mortality reduction.
- BMJ (30 May 2025): Correction to the TESTS trial →Corrected primary-outcome hazard ratio 0.97, 95% confidence interval 0.76–1.24; overall interpretation remains unchanged.
